PDCD1 and non-small cell lung carcinoma: Immunotherapy methods, like inhibitory components essential for breaching an antitumor immune reaction, like PD-1 and programmed cell death ligand 1 (PCDL1), are developed as a result of a finer knowledge of the immunological nature of NSCLC.